Strategic partnerships Be The Match BioTherapies collaborates with cell and gene therapy developers and has a track record of partnerships with Garuda Therapeutics, Chimeric Therapeutics, Orchard Therapeutics, NantKwest, and Celyad, indicating strong potential for new collaboration to source donor material and support end-to-end supply chain needs.

Comprehensive supply The company offers customizable, end-to-end cell therapy supply chain solutions and has managed over 6,500 time-sensitive shipments annually, suggesting opportunities to position as a reliable, scalable provider for both autologous and allogeneic therapies.

Regulatory and data With affiliation to NMDP/Be The Match and involvement in CIBMTR long-term follow-up for FDA-approved CAR-T therapies, there is a selling point around compliant, well-documented donor material and post-therapy data capabilities to de-risk clinical and commercial programs.

Global donor network Access to a global donor sourcing network of over 100,000 volunteers and extensive cell collection capabilities opens upsell opportunities to companies seeking diverse donor material and scalable supply for international trials or launches.

Growth signals Recent leadership additions and ongoing partnerships signal active ecosystem engagement and expansion potential, making Be The Match BioTherapies a persuasive partner for funding rounds, strategic alliances, and accelerated go-to-market programs in cell and gene therapies.